chartexchange

CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

GlobeNewswire Inc. | Nov 9, 2026 7:30 AM EST

Presentation and publication of clinical and biomarker data, regulatory developments,  and 100mg BID dosing regimen support advancement of the neflamapimod clinical development program in dementia with Lewy bodies

Read original article